Bicycle Therapeutics Limited

176 articles about Bicycle Therapeutics Limited

• Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression

  6/8/2022

  Completed Phase I dose escalation; results expected in 3Q22.

• Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference

  6/1/2022

  Bicycle Therapeutics plc announced that management will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022 at 8:00 a.m. ET.

• Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting

  5/26/2022

  Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that the company will present a Trials in Progress poster highlighting the Phase I/II clinical trial of BT7480, a novel, fully synthetic Bicycle TICA™ targeting Nectin-4 and agonizing CD137, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL on June 3-7, 2022.

• Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/5/2022

  Bicycle Therapeutics plc today reported financial results for the first quarter ended March 31, 2022 and provided recent corporate updates.

• Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

  4/11/2022

  Bicycle Therapeutics plc today announced interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4.

• 

  AACR: The Weekend Winners - Amgen, Bicycle and BioNTech

  4/11/2022

  Data presented at the AACR Annual Meeting over the weekend will likely lead to continued stock jumps for Amgen, Bicycle Therapeutics and BioNTech.

• Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

  4/8/2022

  Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, will be presented at the 2022 American Association for Cancer Research Annual Meeting, being held April 8-13, 2022 in New Orleans, LA.

• Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting

  4/7/2022

  Bicycle Therapeutics plc today announced updated preclinical results providing further evidence for Bicycles as a potential novel antiviral modality against SARS-CoV-2.

• Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference

  4/6/2022

  Bicycle Therapeutics plc announced that management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 8:45 a.m. ET.

• Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual Meeting

  3/8/2022

  Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, has been selected for an oral presentation at the upcoming 2022 American Association for Cancer Research Annual Meeting.

• Bicycle Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

  3/8/2022

  Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 8:00 a.m. ET.

• Bicycle Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

  3/1/2022

  Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided recent corporate updates.

• Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

  2/9/2022

  Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 9:20 a.m. ET.

• Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team

  1/5/2022

  Bicycle Therapeutics plc today announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480.

• Bicycle Therapeutics to Participate in Upcoming Investor Conferences - Nov 11, 2021

  11/11/2021

  Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in the following investor conferences in November and December:

• Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting

  11/9/2021

  Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that preclinical data for BT7480, a novel Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA), and BT7455, an EphA2/CD137 Bicycle TICA, will be presented in four poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.

• Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression

  11/4/2021

  Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase I/II trial of BT7480, a novel, fully synthetic Bicycle tumor-targeted immune cell agonist™ targeting Nectin-4 and agonizing CD137.

• Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/4/2021

  Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, reported financial results for the third quarter ended September 30, 2021 and provided recent corporate updates.

• Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal for ImmunoTherapy of Cancer

  11/2/2021

  Bicycle Therapeutics plc today announced that an article highlighting preclinical data from BT7480, a tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing CD137 (4-1BB), was published in the Journal for ImmunoTherapy of Cancer.

• Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration

  10/26/2021

  Bicycle Therapeutics plc today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies.